Brave new world revisited: Focus on nanomedicine.
Cardiovascular disease
Nanomedicine
Nanosafety
Oncology
Theranostics
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
26 11 2020
26 11 2020
Historique:
received:
17
08
2020
accepted:
18
08
2020
pubmed:
15
9
2020
medline:
19
3
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Nanomedicine is at a crossroads: with relatively few success stories in terms of clinical translation despite more and more research on increasingly sophisticated nanomaterials, it is important to consider whether we are on the right track. Indeed, it is crucial that we address the fact that while considerable efforts are being made to overcome barriers to translation from the bench to the clinic, scientists are still struggling to decipher fundamental aspects of nanomaterial interactions with biological systems. We believe that a key to the successful adoption of nanomedicines in oncology and beyond lies in a deeper understanding of underlying biological processes and in decoding interactions between engineered nanomaterials and biological systems. Here we provide an overview of progress in nanomedicine during the past 5 years.
Identifiants
pubmed: 32921412
pii: S0006-291X(20)31642-9
doi: 10.1016/j.bbrc.2020.08.046
pii:
doi:
Substances chimiques
Magnetite Nanoparticles
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-49Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.